Physician profile
Raynor Christopher Casey
NPI 1821014440
$34,324.09
in general payments reported to CMS, 2019-2025
15 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 78% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,712 · 2020: $1,652 · 2021: $4,434 · 2022: $22K · 2023: $899 · 2024: $1,696 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,400 · Travel and Lodging: $15.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,400.00 |
| Travel and Lodging | $15.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $28,614.86 | 2019-2022 | |
| Astellas Pharma US INC | $1,733.47 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $1,486.90 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $915.11 | 2019-2025 | Vabysmo |
| Alcon Vision LLC | $392.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $219.07 | 2019 | |
| Allergan, INC. | $168.33 | 2019-2020 | |
| Abbvie INC. | $162.71 | 2023-2025 | Ozurdex |
| Regeneron Pharmaceuticals, INC. | $139.59 | 2023 | Eylea |
| Apellis Pharmaceuticals, INC. | $122.07 | 2023 | Syfovre |
| Genentech, INC. | $115.93 | 2021 | |
| Notal Vision, INC. | $91.91 | 2019-2025 | Foresee Home |
| Ocular Therapeutix, INC. | $88.80 | 2019 | |
| Harrow Eye, LLC | $58.17 | 2024-2025 | Iheezo |
| Ani Pharmaceuticals, INC. | $14.33 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raynor Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.